168 related articles for article (PubMed ID: 21324135)
1. Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia.
Hill AL; Sun B; Karagianis JL; Watson SB; McDonnell DP
BMC Psychiatry; 2011 Feb; 11():28. PubMed ID: 21324135
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data.
Detke HC; Zhao F; Witte MM
BMC Psychiatry; 2012 May; 12():51. PubMed ID: 22646847
[TBL] [Abstract][Full Text] [Related]
3. Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia.
Mitchell M; Kothare P; Bergstrom R; Zhao F; Jen KY; Walker D; Johnson J; McDonnell D
Clin Ther; 2013 Dec; 35(12):1890-908. PubMed ID: 24184052
[TBL] [Abstract][Full Text] [Related]
4. Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study.
Ascher-Svanum H; Novick D; Haro JM; Bertsch J; McDonnell D; Detke H
BMC Psychiatry; 2013 Sep; 13():224. PubMed ID: 24041270
[TBL] [Abstract][Full Text] [Related]
5. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia.
Kane JM; Detke HC; Naber D; Sethuraman G; Lin DY; Bergstrom RF; McDonnell D
Am J Psychiatry; 2010 Feb; 167(2):181-9. PubMed ID: 20008947
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study.
McDonnell DP; Landry J; Detke HC
Int Clin Psychopharmacol; 2014 Nov; 29(6):322-31. PubMed ID: 24850228
[TBL] [Abstract][Full Text] [Related]
7. Comparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized, open-label study in outpatients with schizophrenia.
Detke HC; Weiden PJ; Llorca PM; Choukour M; Watson SB; Brunner E; Ascher-Svanum H
J Clin Psychopharmacol; 2014 Aug; 34(4):426-34. PubMed ID: 24781441
[TBL] [Abstract][Full Text] [Related]
8. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia.
Lauriello J; Lambert T; Andersen S; Lin D; Taylor CC; McDonnell D
J Clin Psychiatry; 2008 May; 69(5):790-9. PubMed ID: 18452346
[TBL] [Abstract][Full Text] [Related]
9. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases.
Detke HC; McDonnell DP; Brunner E; Zhao F; Sorsaburu S; Stefaniak VJ; Corya SA
BMC Psychiatry; 2010 Jun; 10():43. PubMed ID: 20537128
[TBL] [Abstract][Full Text] [Related]
10. Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine.
McDonnell DP; Kryzhanovskaya LA; Zhao F; Detke HC; Feldman PD
Hum Psychopharmacol; 2011 Aug; 26(6):422-33. PubMed ID: 21823172
[TBL] [Abstract][Full Text] [Related]
11. Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.
Stauffer VL; Sniadecki JL; Piezer KW; Gatz J; Kollack-Walker S; Hoffmann VP; Conley R; Durell T
BMC Psychiatry; 2010 Nov; 10():89. PubMed ID: 21047395
[TBL] [Abstract][Full Text] [Related]
12. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia.
Kane JM; Osuntokun O; Kryzhanovskaya LA; Xu W; Stauffer VL; Watson SB; Breier A
J Clin Psychiatry; 2009 Apr; 70(4):572-81. PubMed ID: 19323965
[TBL] [Abstract][Full Text] [Related]
13. A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection.
Atkins S; Detke HC; McDonnell DP; Case MG; Wang S
BMC Psychiatry; 2014 Jan; 14():7. PubMed ID: 24423017
[TBL] [Abstract][Full Text] [Related]
14. Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia.
Witte MM; Case MG; Schuh KJ; Ascher-Svanum H
Curr Med Res Opin; 2012 Mar; 28(3):315-23. PubMed ID: 22236137
[TBL] [Abstract][Full Text] [Related]
15. Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study.
Ganguli R; Brar JS; Mahmoud R; Berry SA; Pandina GJ
BMC Med; 2008 Jun; 6():17. PubMed ID: 18590519
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.
Chrzanowski WK; Marcus RN; Torbeyns A; Nyilas M; McQuade RD
Psychopharmacology (Berl); 2006 Dec; 189(2):259-66. PubMed ID: 17058105
[TBL] [Abstract][Full Text] [Related]
17. The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: a pooled analysis of 4 clinical trials.
Kryzhanovskaya LA; Robertson-Plouch CK; Xu W; Carlson JL; Merida KM; Dittmann RW
J Clin Psychiatry; 2009 Feb; 70(2):247-58. PubMed ID: 19210948
[TBL] [Abstract][Full Text] [Related]
18. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
19. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
[TBL] [Abstract][Full Text] [Related]
20. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
